8-K ·Filed Apr 10, 2026
8-K context-dependent: Items 5.02
Actionable Insight • Neutral
Monitor for any further executive changes or delays in financial reporting that could signal deeper organizational issues, especially given the company's small size and emerging growth status.
Final — all horizons settled through T+60d
KLRS ▼ -25.36% at T+60d
NEUTRAL call -25.36% · α vs SPY -34.28% · entry $6.31 → $4.71
T+1d
-7.77%
call -7.77% · α -8.98%
$5.82
settled 7mo ago
T+5d
+4.60%
call +4.60% · α +1.30%
$6.60
settled 6mo ago
T+20d
-25.04%
call -25.04% · α -32.77%
$4.73
settled 6mo ago
T+60d
-25.36%
call -25.36% · α -34.28%
$4.71
settled 4mo ago
Price Chart
Loading chart...
Executive Summary
Kalaris Therapeutics CFO Matthew Gall resigned effective April 14, 2026, with Chief Accounting Officer Brett Hagen stepping in as principal financial officer. No changes to Hagen's compensation were made.
Key Facts
- CFO Matthew Gall resigned effective April 14, 2026
- Brett Hagen, Chief Accounting Officer since January 2019, appointed as principal financial officer
- No changes to Hagen's compensatory arrangements
- Filing made on April 10, 2026, reporting event from April 8, 2026
Financial Impact
No immediate financial impact disclosed
executive leadershipgovernance
Risk Factors
- Potential leadership instability following CFO departure
- Risk of operational disruption during transition period
Market Snapshot
Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-151215 |
| Document: 0001193125-26-151215-index-headers.html | 0001193125-26-151215 |
| Document: 0001193125-26-151215-index.html | 0001193125-26-151215 |
| Document: 0001193125-26-151215.txt | 0001193125-26-151215 |
16 reports for KLRS
40% Hit rate @ T+60 Went positive at some point 2 of 5 best @ T+60▲ +27.75%
Filters
Rows
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | SC 13G | $1.80 | awaiting T+60 | — | $1.81 (+0.56%) |
Aug 11, 2026 11w ago | 8-K | $3.97 | awaiting T+60 | — | $1.81 (−54.41%) |
Aug 11, 2026 11w ago | Press Release | $3.97 | awaiting T+60 | — | $1.81 (−54.41%) |
Aug 3, 2026 12w ago | 3 | $4.32 | awaiting T+60 | — | $1.81 (−58.10%) |
Jul 20, 2026 14w ago | 8-K | $4.00 $2.23 | ▼ −44.25% | ▼ −49.09% | $1.81 (−54.75%) |
Jul 17, 2026 14w ago | 8-K | $4.38 $2.26 | ▼ −48.40% | ▼ −53.09% | $1.81 (−58.68%) |
Jul 17, 2026 14w ago | Press Release | $4.38 $2.26 | ▼ −48.40% | ▼ −53.09% | $1.81 (−58.68%) |
Jun 11, 2026 19w ago | Institutional Cluster | $4.36 $3.90 | ▼ −10.55% | ▼ −14.95% | $1.81 (−58.49%) |
May 12, 2026 24w ago | 8-K | $4.79 $4.19 | ▼ −12.53% | ▼ −16.91% | $1.81 (−62.21%) |
May 12, 2026 24w ago | Press Release | $4.79 $4.19 | ▼ −12.53% | ▼ −16.91% | $1.81 (−62.21%) |
Showing 10 of 16
US Market Status
Market Open — Closes in 3h 39m
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers